An analyst has two synthetic peptides on the bench that give the same intact mass to the fourth decimal place and elute seconds apart on reverse-phase HPLC. One was ordered as the intended sequence; the other came from a synthesis where two neighboring residues may have been coupled in the wrong order. Intact mass cannot settle the matter, because swapping two residues leaves the total mass untouched. The question is no longer what the molecule weighs but in what order its building blocks are joined, and that is the question tandem mass spectrometry was designed to answer.
Two stages of mass analysis around one selected ion
Tandem mass spectrometry, usually written MS/MS, performs mass analysis twice with a fragmentation step in between. The first stage surveys the ions arriving from the source and isolates one of them by its mass-to-charge ratio. That selected ion, the precursor, is then broken apart, and the second stage records the masses of the pieces. Because only the precursor was fragmented, every product ion in the resulting spectrum belongs to that one species, even if other compounds were entering the instrument at the same moment.
The isolation window is a genuine compromise. A wide window passes more of the precursor’s isotope cluster and gives a stronger signal, but it also admits any co-eluting neighbor of similar mass, so two species can be fragmented together and their product ions superimposed. A narrow window keeps the spectrum clean but loses intensity. Multiply charged precursors, typical of electrospray, tend to fragment more informatively. The intact-mass measurement that normally comes first is covered in our article on mass spectrometry and peptide identity.
Where a peptide chain breaks, and what the detector sees
In collision-induced dissociation the precursor is accelerated into an inert gas. The collisions deposit internal energy, and the peptide most readily releases it by cleaving an amide bond in the backbone. Each cleavage produces two pieces, and only the piece that keeps the charge is detected. If the charge stays on the N-terminal piece, the fragment is called a b ion; if it stays on the C-terminal piece, it is a y ion.
Different molecules break at different amide bonds. The spectrum therefore collects a family of b ions of increasing length, counted from the N-terminus, and a family of y ions of increasing length, counted from the C-terminus. The two families are complementary: a b ion and the y ion produced by the same cleavage together account for the whole precursor, so their masses sum to a fixed value set by the precursor mass. That relationship lets an analyst test whether a candidate peak truly belongs to a series.
The sequence is written in the spacing
No single fragment peak reveals the sequence. The information lies in the distance between adjacent members of a series. Moving from one b ion to the next adds exactly one residue, so the mass difference identifies that residue. A step of 71.037 corresponds to alanine; 113.084 corresponds to leucine or isoleucine; 128.059 points to glutamine, while 128.095 points to lysine.
Two details matter here. First, these are residue masses, not the masses of free amino acids: a peptide bond forms with loss of water, so each residue weighs its free amino acid minus one water molecule. Second, the arithmetic must use monoisotopic masses throughout. Mixing in average values introduces errors larger than the differences being resolved.
Beyond b and y: other fragments and other activation methods
Collisional spectra are rarely tidy. Smaller populations of a and c ions arise on the N-terminal side, and x and z ions on the C-terminal side. A chain broken in two places gives internal fragments that contain neither terminus. Immonium ions report that a residue is present without saying where.
Electron-based dissociation methods cleave a different backbone bond and produce mainly c and z ions. Their practical value is that they break the backbone without first stripping off labile modifications. A phosphate or glycan that collisional activation would knock off before the chain fragments tends to stay attached, so its position on the chain can be located.
Ambiguities no instrument setting removes
Some limits are built into the physics rather than the hardware:
| Situation | What the fragment spectrum shows | What actually settles it |
|---|---|---|
| Leucine vs isoleucine | Identical residue mass; ordinary fragmentation cannot separate them | Expected sequence, or specialized fragmentation and orthogonal methods |
| D vs L residue | Identical mass at every stage | A chiral separation method, not mass spectrometry |
| Glutamine vs lysine | Steps differ by only 0.036 | Sufficient mass accuracy and resolution |
| Proline in the chain | Enhanced cleavage on one side, suppressed on the other; gaps and unusually intense peaks | Complementary series and careful coverage reporting |
| Bonds that resist cleavage | Missing rungs in the series | Inference by mass balance, stated as inference |
When a report assigns leucine rather than isoleucine at a given position, that assignment almost always came from the sequence the analyst expected, not from the spectrum itself.
Report what was observed, and mark what was inferred
Complete fragment series are the exception. Consider a ten-residue peptide with nine backbone amide bonds. If the spectrum contains fragments spanning six of those junctions, six are confirmed by observation and three are filled in because the remaining mass balances. A careful report states which stretches were covered by observed ions and which were assigned by difference. A sequence printed in full with no coverage information overstates what the experiment proved.
MS/MS is also a good way to explain unexpected masses from synthesis. A deletion sequence missing one residue, or a chain still carrying a protecting group, shows up as a shifted series from the point of the defect onward. The common classes of such byproducts are described in peptide synthesis impurities.
Sequence evidence is not purity evidence
Because the first stage isolates one precursor, MS/MS says nothing about how much of the sample that precursor represents. It confirms that the selected species has the expected residue order. The proportion of the main component relative to everything else is a chromatographic question, answered by the approach explained in reverse-phase HPLC for peptide purity and read as described in how to read an HPLC chromatogram.
For short synthetic peptides, intact mass plus a purity trace is normally an adequate level of evidence, and routine supplier documentation rarely includes fragment sequencing. Battle Born publishes an independent reverse-phase HPLC result for each product; a laboratory that needs sequence-level confirmation for its own records would commission MS/MS separately. The technique earns its cost in three situations: when two candidate sequences share a mass, when a modification must be pinned to a specific residue, and when a chain is long enough that intact mass no longer constrains the answer.
Questions
Is MS/MS the same as peptide mapping?
No. Peptide mapping first digests a larger molecule with a protease and then characterizes the pieces, often using MS/MS on each one. Tandem mass spectrometry is the fragmentation measurement itself and can be applied to an intact short peptide without any digestion step.
Why can two peptides with the same composition not be told apart by intact mass?
Mass depends only on which atoms are present. Rearranging the order of residues changes structure but not composition, so the total mass is unchanged. Only fragmentation, which reports masses of partial chains, exposes the order.
Does a matching fragment spectrum prove the material is pure?
It does not. It shows that the isolated precursor has the expected sequence. Other components in the sample were excluded by the isolation step and are not represented in the spectrum at all.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.